BIBW 2992

Known as: BIBW-2992, BIBW2992 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2016
051020062016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
7525^ Background: Despite initial responses to reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
Is this relevant?
2011
2011
Afatinib (BIBW 2992), a novel aniline-quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity… (More)
Is this relevant?
2011
2011
This Phase I study determined the maximum-tolerated dose (MTD) of afatinib (Afatinib is an investigational compound and its… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Preclinical data have demonstrated that BIBW 2992 is a potent irreversible inhibitor of ErbB1 (EGFR/HER1) and mutated… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
EGFR is a major anticancer drug target in human epithelial tumors. One effective class of agents is the tyrosine kinase… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
2006
2006
2074 Background: BIBW 2992 is a novel, potent, orally bioavailable irreversible inhibitor of both EGFR and HER2 receptor tyrosine… (More)
Is this relevant?